Search Results

Gilgamesh Pharmaceuticals today announced that it has been awarded a multi-year $14 million grant from the National Institute on Drug Abuse (NIDA) to develop GM-3009, its novel, cardiac-safe ibogaine analog for the treatment of substance use disorders.

Cessation Therapeutics, Inc. today announced that it has been awarded an additional grant from the National Institute on Drug Abuse (NIDA, a division of the National Institutes of Health).

Tris Pharma, Inc. announced that the company has been awarded a grant expected to provide up to $16.6M over five years from the National Institute on Drug Abuse, part of the National Institutes of Health.

MAPS Public Benefit Corporation (“MAPS PBC”) announced that the National Institute on Drug Abuse (“NIDA”), part of the National Institutes of Health, has agreed to provide data to supplement the company’s new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for MDMA-assisted therapy as a treatment for post-traumatic stress disorder (“PTSD”).

Macomics Ltd, a leader in macrophage drug discovery, announces that it has entered a scientific collaboration with Prof. Andrea Alimonti at IOR, one of Switzerland’s leading research institutes.

Xylyx Bio, Inc. announced that it has been awarded a Small Business Innovation Research Fast-Track grant from the National Cancer Institute of the National Institutes of Health to advance commercial development of its InMatrico® disease modeling and drug testing platform to help scientists discover and test drug candidates for metastatic breast cancer.

Camino Pharma, LLC announced that its co-founder and CSO, Reto Gadient, Ph.D., has been awarded a two-year, $1.97M grant by the National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health under Award Number U43AA031388 and is the Principal Investigator on the grant.

Scientists at Camino Pharma, LLC, Sanford Burnham Prebys and University of California San Diego School of Medicine received a $9-million grant from the National Institute on Drug Abuse at the National Institutes of Health.

Delix Therapeutics today announced it has been awarded a $320,000 grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to support the advancement of DLX-007.